ASH 2020 | Approved and emerging antibody-based therapies in myeloma
Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, outlines current and emerging antibody therapies in multiple myeloma, an area in which he recently published a review in Best Practice & Research Clinical Haematology. The approval of the first monoclonal antibody therapies, daratumumab and elotuzumab, in relapsed/refractory myeloma has generated lots of research interest in this area. The drugs have shown significant clinical benefit, and with further investigation into combination therapies, are expected to revolutionize the treatment armamentarium in myeloma. These approvals represent the beginning of antibody treatment development, with belantamab mafodotin, a BCMA-targeted antibody-drug conjugate being approved in 2020, and development of many more therapies underway. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consulting: GenMab, Amgen, Boehringer Ingelheim, Janssen, Bristol-Myers Squibb
Research funding: Genentech, Pfizer, Janssen, Bristol-Myers Squibb
Patent: Serametrix
